Abstract Legislation in individual member states of the European Union on human embryonic stem cell (hESC) research is as divergent as the different cultural, ethical, and religious views on the issue. On the occasion of the public launch of the European Human Embryonic Stem Cell Registry (hESCreg: www.hescreg.eu), a two-day symposium was held on 18 and 19 January 2008 in Berlin to offer participants an overview of state-of-the-art hESC research and legislation throughout Europe and in selected regions of the world. Thirty leading scientists from Europe as well as from the United States, Japan, and Australia reported on a range of aspects related to research on hESC and reviewed the key elements of the newly established hESCreg database of hESC lines. In this article we summarize and complete the information on the current status of international hESC regulation. © 2008 Published by Elsevier B.V.
hESCreg reflects European and international pluralism
The European Human Embryonic Stem Cell Registry (hESCreg) is an online database that provides a comprehensive source of information on all human embryonic stem cell (hESC) lines that have been derived within the European Union (EU) and beyond (Borstlap, 2008; Sipp, 2008) . It provides scientists and the public at large with optimal and free access to several lines of information on hESC. Providers of hESC lines are being registered to provide detailed characteristics of the cell lines derived. Research groups and stem cell banks can register to provide information on their research projects. The minimum registration criteria encompass information on the origin of the cell line and its availability, its consented and traceable procurement, and genetic information, as well as differentiation potential and analysis of pluripotent marker expression. Additional information includes details on culture conditions, further hESC markers, and derivation information as well as regulatory and ethical information .
As of December 2008 hESCreg has registered 217 cell lines derived in the EU and Europe-associated countries (see Table 2 ) and 302 hESC lines derived outside Europe. Some 49 additional lines are being registered through the U.K. Stem Cell Bank as well as 8 lines through the U.S. National Stem Cell Bank (at WiCell).
Differing views in the individual EU member states are reflected in a multitude of national legislations on stem cell research (Bosch, 2005) . Legislation usually applies to procurement of embryos for research, preimplantation genetic diagnostic techniques (PGD), and research on and derivation of hESC lines from (a) supernumerary "IVF" embryos, i.e., human embryos created for medically assisted fertilization (IVF) that are no longer intended for clinical use, and (b) embryos created for research, i.e., human embryos created by IVF with donated gametes and not intended to induce pregnancy. Creation of embryos by somatic cell nuclear transfer (SCNT) is referred to here as "therapeutic cloning."
Ethical guidelines in Europe
Despite the divergent hESC legislation in Europe, the ethical concern in Europe is unifying. European countries in which hESC research is allowed carry out experiments in accordance with the following fundamental ethical principles and human rights laws of the European Union: (1) personal protection rights (protection of human life), (2) political rights (e.g., no inappropriate state intervention), and (3) social and economic rights. Research on hESC in Europe, therefore, meets a number of basic rules and requirements: scientific necessity and high-ranking research objectives, urgency, social desirability, and primacy of personal wellbeing and interests of the individual over the sole interests of science and society. Furthermore, in countries where research on hESC lines is allowed, it may be carried out on hESC lines only if deemed necessary, if there are no valid alternatives, and if the work is nonredundant.
hESC research and legislation in selected European and Europe-associated countries By 2001, only a few member states such as Great Britain, Belgium, and Sweden had enacted specific laws on the use of embryos for research, but by 2008 around 16 EU and Europeassociated countries have introduced legislation to regulate stem cell research. While many countries in Europe are moving to enable stem cell research using embryo-derived stem cells through new legislation, the situation regarding the specific nature of regulation across Europe is still quite complex (Table 1, Fig. 1 ).
The following sections describe the legal situation in the EU and Europe-associated countries that are members of the European human embryonic stem cell registry (see Table 2 ) and from which delegates were provided with information on hESC research legislation during the hESCreg launch symposium. The subsequent sections present the legal situation in the United States and in the Asian-Pacific countries.
Belgium
In Belgium the Law on Research on Embryos in vitro from 2003 (Loi relatif à la recherche sur les embryons in vitro: http://www.eshre.com/emc.asp?pageId=751) forbids the creation of embryos for medical research unless the objective of the project cannot be achieved using supernumerary IVF embryos. Research on supernumerary embryos is acceptable if (a) it concerns research in the area of fertility, sterility, organ and tissue transplantation, or prevention or treatment of diseases; (b) the research is based on the latest research methodologies; (c) the research is conducted at an accredited facility at a university clinic for reproductive medicine or medical genetics; (d) the research is supervised by a specialized physician or a scientist with necessary qualifications; (e) the age of the embryo is not greater than 14 days; and (f) the local ethics committee has approved. Therapeutic cloning for medical research is allowed, reproductive cloning is forbidden. It is forbidden to use embryos, gametes, or embryonic stem cells for commercial purposes. The procurement of and research on hESC from supernumerary IVF embryos are allowed (Pennings, 2007 Therapeutic cloning for research purposes as well as for the development of new therapies is not explicitly prohibited by law and is subject to case-by-case decisions of the respective institutional ethical bodies. In contrast, the Czech act clearly prohibits any manipulation that could lead to the creation of a new human individual, the so-called reproductive cloning. hESC may be derived from supernumerary IVF embryos. hESC lines on which research is performed must be listed in the Czech central registry, which is open to the public. Two institutions, one in Brno (Masaryk University) and one in Prague (Institute of Experimental Medicine Academy of Sciences of the Czech Republic), with around six research groups are involved in hESC research.
Denmark
In Denmark research is allowed on embryos if it can lead to the improvement of IVF or PGD methods and the obtainment of important new knowledge applicable to therapies for human diseases. This is covered by the Act of Artificial Figure 1 The status of hESC research legislation throughout the EU and Europe-associated countries. The four colors represent the four positions on hESC research in Europe: green, hESC research and derivation of hESC lines from supernumerary IVF embryos permitted (dark green, therapeutic cloning permitted; light green, therapeutic cloning prohibited); orange, hESC research permitted only with imported hESC lines-hESC derivation and SCNT prohibited; red, prohibition of any hESC research; grey, no hESC-specific legislation in place. the embryos used have been created in vitro for reproductive issues and failed to be suitable for that purpose; (c) if both parents have given written consent; (d) if the research protocol has been specifically approved by the ministries responsible for research and health (competent authority: Agence de la Biomedicine); and (e) if the embryo is destroyed within 7 days after fertilization. Both therapeutic cloning and reproductive cloning are prohibited. Contraventions to the reproductive cloning ban carry a penalty of up to 30 years imprisonment and a fine of up to €7,500,000. The procurement of hESC lines is allowed from supernumerary IVF embryos as well as from those that have been identified as unsuitable for implantation following preimplantation diagnosis. The first French hESC line was derived in October 2007 from such a PGD embryo carrying a monosomy 21 and a trisomy 1 (http://ist. inserm.fr/basispresse/CPS/CPS2007anglais/23october2007. pdf). To achieve the greatest possible transparency the embryos and hESC lines used are registered. Currently hESC research is authorized in around 34 authorized laboratories.
Finland
The Medical Research Act (Laki lääketieteellisestä tutkimuksesta: http://www.finlex.fi/fi/laki/ajantasa/1999/ 19990488) from 1999 forbids the production of embryos for research purposes in Finland. However, embryos created by therapeutic cloning might not be considered embryos by law ("living group of cells resulting from fertilization") and could possibly be procured. The research on such embryos is allowed only for 14 days after fertilization, after which the embryo has to be destroyed. Donated gametes have to be used within 10 years. Gametes and ovarian tissue for the patient's own use can be stored in liquid nitrogen for an unlimited period of time. There are no restrictions on research with PGD embryos, nor on the procurement of and research on hESC that have been derived from supernumerary PGD or IVF embryos. Reproductive cloning and the production of chimeras are prohibited by law. Research centers are at the University of Helsinki, the University of Tampere, the University of Turku, the University of Kuopio, and the University of Oulu.
Germany
In April 2008, Germany amended its Stem Cell Act (Stammzellgesetz: http://www.bmj.bund.de/enid/77e71f1a0cb444-ca3eabd0cff43559fd,33d0e45f7472636964092d0933303334/ Menschenrechte/Bioethik_xb.html), which generally forbids any use of hESC, but also grants certain exceptions to the law. Researchers wishing to import or use hESC must submit an application for license on a case-by-case basis. Imported hESC lines must be derived from supernumerary embryos from 
Hungary
In Hungary, embryos cannot be created for research purposes. Only embryos created in assisted reproductive procedures can be used for research on the basis of the decision of the Hungarian Reproduction Commission and as regards the Health Care Act (CLIV/1997: www2.ohchr.org/ english/bodies/cescr/docs/E.C.12.HUN.3-Annex10.pdf). Embryos on which experiments were carried out cannot be implanted into the human body and cannot be kept alive for more than 14 days. For the unique purpose of investigating on the probable illness of the child to be born, separation of the cells of the embryo is allowed. hESC derivation is not allowed. With special permission from the Hungarian Reproductive Council, which regulates all hESC work in Hungary, the import of hESC is permitted. Licenses that were given so far are few and up until now (as of December 2008) only one research group is actively working with hESC lines.
Israel
Israel takes third place worldwide as regards publications of research teams that have utilized hESC in research experiments (Löser et al., 2008 . If the board accepts the application, the couple may be treated abroad and the expenses will be covered by the health service. Stem cell procurement from supernumerary IVF embryos for medical and biological research and education is allowed as well. Cloning (therapeutic) and the use of techniques aimed at the production of genetically identical individuals are prohibited. The act will be reviewed every 4 years and amendments are expected in June 2011.
Portugal
In Portugal the Law on Medically Assisted Procreation (Lei no. 32/2006 Procriação medicamente assistida: http://www. dre.pt/pdfgratis/2006/07/14300.pdf ) from 2006 prohibits the creation of embryos for research but allows research on supernumerary IVF embryos or those with severe genetic disorders. It is also permissive if the envisaged project will benefit humankind and aims at prevention, diagnosis, or therapy as well as the perfection of medically assisted reproduction techniques. Embryos that have not been created through the fertilization of a human oocyte by a human sperm, a condition that includes therapeutic cloning techniques, might be allowed but only for research purposes. 
Conclusion
Since there is no single universally accepted view on the ethical, legal, and moral status of the embryo as such, nor on the use of hESC lines derived thereof, one of the registry's tasks is to reflect European and international pluralism adequately and provide appropriate methods of safeguarding high standards in relation to ethical concerns and transparency in research. Eventually this may prevent the unnecessary development of new cell lines, avoid the duplication of research work, and consolidate Europe's position in the field. hESCreg is already the most comprehensive registry of its kind worldwide and will contribute to strengthening the role of the European Union in embryonic stem cell research at the international level. Consequently, the European Commission has issued hESCreg with the mandate to act as the central reference for all funding decisions on proposed hESC research projects within the Commission's Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007) (2008) (2009) (2010) (2011) (2012) (2013) . The registry is actively engaged in the societal discourse on research into human embryonic stem cells, a debate with direct impact on the next Framework Programme after 2013. 
